These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
22. The evolving paradigm of second-line hormonal therapy options for castration-resistant prostate cancer. Courtney KD; Taplin ME Curr Opin Oncol; 2012 May; 24(3):272-7. PubMed ID: 22327837 [TBL] [Abstract][Full Text] [Related]
23. Abiraterone acetate in combination with prednisone in the treatment of prostate cancer: safety and efficacy. Manceau C; Mourey L; Pouessel D; Ploussard G Expert Rev Anticancer Ther; 2020 Aug; 20(8):629-638. PubMed ID: 32552120 [TBL] [Abstract][Full Text] [Related]
24. Enzalutamide versus abiraterone acetate for the treatment of men with metastatic castration-resistant prostate cancer. Zhang T; Zhu J; George DJ; Armstrong AJ Expert Opin Pharmacother; 2015 Mar; 16(4):473-85. PubMed ID: 25534660 [TBL] [Abstract][Full Text] [Related]
25. A bypass mechanism of abiraterone-resistant prostate cancer: Accumulating CYP17A1 substrates activate androgen receptor signaling. Moll JM; Kumagai J; van Royen ME; Teubel WJ; van Soest RJ; French PJ; Homma Y; Jenster G; de Wit R; van Weerden WM Prostate; 2019 Jun; 79(9):937-948. PubMed ID: 31017696 [TBL] [Abstract][Full Text] [Related]
26. Phase I and II therapies targeting the androgen receptor for the treatment of castration resistant prostate cancer. Dellis A; Papatsoris AG Expert Opin Investig Drugs; 2016 Jun; 25(6):697-707. PubMed ID: 26954621 [TBL] [Abstract][Full Text] [Related]
27. Update on Systemic Prostate Cancer Therapies: Management of Metastatic Castration-resistant Prostate Cancer in the Era of Precision Oncology. Nuhn P; De Bono JS; Fizazi K; Freedland SJ; Grilli M; Kantoff PW; Sonpavde G; Sternberg CN; Yegnasubramanian S; Antonarakis ES Eur Urol; 2019 Jan; 75(1):88-99. PubMed ID: 29673712 [TBL] [Abstract][Full Text] [Related]
28. Androgen synthesis inhibitors in the treatment of castration-resistant prostate cancer. Stein MN; Patel N; Bershadskiy A; Sokoloff A; Singer EA Asian J Androl; 2014; 16(3):387-400. PubMed ID: 24759590 [TBL] [Abstract][Full Text] [Related]
29. Advances in hormonal therapies for hormone naïve and castration-resistant prostate cancers with or without previous chemotherapy. Pham T; Sadowski MC; Li H; Richard DJ; d'Emden MC; Richard K Exp Hematol Oncol; 2015; 5():15. PubMed ID: 27340608 [TBL] [Abstract][Full Text] [Related]
30. CYP17 inhibitors in prostate cancer: latest evidence and clinical potential. Alex AB; Pal SK; Agarwal N Ther Adv Med Oncol; 2016 Jul; 8(4):267-75. PubMed ID: 27482286 [TBL] [Abstract][Full Text] [Related]
31. Emerging novel therapies for advanced prostate cancer. Osanto S; Van Poppel H Ther Adv Urol; 2012 Feb; 4(1):3-12. PubMed ID: 22295041 [TBL] [Abstract][Full Text] [Related]
36. Optimizing the care of patients with advanced prostate cancer in the UK: current challenges and future opportunities. Payne H; Bahl A; Mason M; Troup J; De Bono J BJU Int; 2012 Sep; 110(5):658-67. PubMed ID: 22429837 [TBL] [Abstract][Full Text] [Related]
37. Androgen Receptor Splice Variant 7 and Efficacy of Taxane Chemotherapy in Patients With Metastatic Castration-Resistant Prostate Cancer. Antonarakis ES; Lu C; Luber B; Wang H; Chen Y; Nakazawa M; Nadal R; Paller CJ; Denmeade SR; Carducci MA; Eisenberger MA; Luo J JAMA Oncol; 2015 Aug; 1(5):582-91. PubMed ID: 26181238 [TBL] [Abstract][Full Text] [Related]
38. Translating scientific advancement into clinical benefit for castration-resistant prostate cancer patients. Attard G; de Bono JS Clin Cancer Res; 2011 Jun; 17(12):3867-75. PubMed ID: 21680542 [TBL] [Abstract][Full Text] [Related]
39. Castration-resistant prostate cancer: from new pathophysiology to new treatment. Sridhar SS; Freedland SJ; Gleave ME; Higano C; Mulders P; Parker C; Sartor O; Saad F Eur Urol; 2014 Feb; 65(2):289-99. PubMed ID: 23957948 [TBL] [Abstract][Full Text] [Related]